Program
HS235
A development code.
Its studies are mostly in Hypertension, Pulmonary · Pulmonary Arterial Hypertension · Obesity, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| 35Pharma Inc., a GSK | 22 open or running | phase 2since Aug 8, 2025 | Aug 8, 2025 | Mar 2028phase 2 · NCT07143448 |
| 35Pharma | 10 open or running | phase 1since Nov 27, 2024 | Nov 27, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 27, 2024First study: phase 1 study in OverweightNew to 35Pharma35Pharma · NCT06714825 · 39 enrolled · Canada
- Aug 8, 202535Pharma Inc., a GSK's first studies: 2 phase 2 studiesNew to 35Pharma Inc., a GSK35Pharma Inc., a GSK · NCT07123779, NCT07143448
Ahead
- Mar 2028Primary completion: phase 2 study in Pulmonary Arterial Hypertension35Pharma Inc., a GSK · NCT07143448
- Jan 2029Primary completion: phase 2 study in Hypertension, Pulmonary35Pharma Inc., a GSK · NCT07123779
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07143448Pulmonary Arterial Hypertension · United States, Spain, United Kingdom | 2 | Recruiting | 35Pharma Inc., a GSK | Mar 2028 | 90 |
| NCT07123779Hypertension, Pulmonary · United States | 2 | Recruiting | 35Pharma Inc., a GSK | Jan 2029 | 126 |
| NCT06714825Overweight · Canada | 1 | Completed | 35Pharma | Dec 2, 2025 | 39 |
How it is read
Names in the registry
- “HS235”, 3 entries
Codes read as this program: HS235.
Conditions, from the studies’ own filings
- Hypertension, Pulmonary, 1 study
- Pulmonary Arterial Hypertension, 1 study
- Obesity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.